Right vein, first time, every time.

ICU_IV_1.jpg
 

MAKING SIMPLE  PROCEDURES SIMPLE

We're on a mission to improve the cannulation experience on both sides of the needle. Cannulation is often the first key procedural step in a patient's clinical care journey, but it's frequently filled with fear as clinicians often fail to find the right vein the first time. This can lead to pain, anxiety, complications, and delayed treatments. We're currently in product development to bring this concept to life and solve this painful problem for patients and health care providers around the world.

IOTYA0334.jpg
 

INTRODUCING VEINTECH

After coming together though and winning the Perth Biodesign program in 2019, Nikhilesh Bappoo, Nicholas Buckley & Dr Katherine Arenson have been pushing forward with their award winning design concept. With their bench prototype completed and alpha prototype in development, VeinTech are positioned to solve a common pain-point in health care around the world: the high rate of first pass cannulation failure rates. With their ultra portable hand held vein imaging device, the VeinWave, they aim to help clinicians successfully target the right vein, first time, every time.

Perth BioDesign.png

2019 OVERALL WINNER

jtsi.jpeg

2020 INNOVATION VOUCHER

Curtin Logo.png

2020 INNOVATION AWARDS FINALIST

MedTech Accuator.png

2021 ASIA-PACIFIC WINNER

IOTY 2021-1.jpg

2021 FINALIST

IOTY 2021-2.jpg

2021 WINNER

Incite Awards.png

2021 FINALIST

2021 WA MTP MANUFACTURING VOUCHER

 
Nurse And Patient

"Every time I ask my nursing staff what their biggest problem is and what I can do to help, it is always cannulation."

PROF. FIONA WOOD AM

 

THE PROBLEM

Since the advent of intravenous cannulas in the 1950’s, clinicians have used subjective judgement through visual examination and manual palpation to estimate the location and quality of veins to target with a needle for cannulation. 70 years on, the average insertion failure rate is still 40%, and up to 70% in individuals with difficult intravenous access (DIVAs) such as children, chemotherapy and obese patients. These unnecessary  failures results in pain and stress for both patients and clinicians, increasing the risk of complications and delaying care.

 
noun_Patient_2070999-blue.png

70%

INPATIENTS REQUIRE A CANNULA

noun_cannula_3804412-blue.png

40%

FAIL ON FIRST INSERTION ATTEMPT

noun_Coins_3804348-blue.png

$70

COST PER MISSED ATTEMPT

noun_Hospital_879706-blue.png

$16B

DIVAS EST. COST TO GLOBAL HEALTHCARE

 

OUR SOLUTION

VeinWave is a handheld ultraportable unit designed to assist with visualising veins to target for cannulation. It is designed to minimize training requirements and cost, therefore allowing for widespread adoption. 

VeinWave aims to significantly reduce the first-pass failure rate of 40%. By finding the right veins faster, we envision better patient satisfaction, lower risks of complications and improved clinical efficiency.

In Australia alone, 10 million cannulas fail on first insertion every year, resulting in an AU$700 million burden. With a global increasing trend of chronic disease and obesity, the failure rate continues to grow, representing a significant market opportunity for VeinTech and the VeinWave technology.

 
VT0007.jpg
noun_easy_2742915-white.png

EASY TO USE

Medical white.png

MINIMAL TRAINING

noun_affordability_3451798-white.png

AFFORDABLE

 
VeinWave Render - Display.png
 

EXECUTIVE TEAM

VeinTech-Team-2021-10.jpg

DR KATHERINE ARENSON

Co-founder, Director and Chief Medical Officer

MBChB, FACEM
 

Emergency Medicine, Armadale Hospital

VeinTech-Team-2021-7.jpg

NIKHILESH BAPPOO

Co-founder, Director and Chief Technology Officer

BPhil, MPE, PhD (cand) in
Vascular Engineering


Product, Regulatory & Quality Affairs, VitalTrace

VeinTech-Team-2021-4.jpg

NICHOLAS BUCKLEY

Co-founder, Director and Chief Executive Officer

BSc (Physiotherapy), PhD (cand) in Physiotherapy

Jamie-Davison-Carbon-Group.jpg

JAMIE DAVISON

Chief Financial Officer

AICD, CPA, MIntEcon&F, BBus Man, BCOM

Co-founder, Carbon Group

 

ADVISORY BOARD

Mark+Ryan,+Non-Executive+Director+of+DC+Alliance.jpg

MARK RYAN

Director, Cytomatrix Pty Ltd and Pier DC Pty Ltd

Barry-Doyle.jpg

DR BARRY DOYLE

Head of Cardiovascular Medicine, Harry Perkins Institute & UWA

Co-founder & Director, Navier Medical and Flomatrix

1517714582944.jpg

LIDDY MCCALL

Investment Director, Yuuwa Capital

1517744611261.jpg

DR JULIAN SHAPLEY

Co-founder, Glucose Republic

Entrepreneur in residence, Biodesign Australia

1638424637552.jpg

PROF. KEVIN PFLEGER

Chair Advisory Board

Director, Biomedical Innovation, UWA & MTP Connect WA Life Sciences Innovation Hub

OUR GENEROUS SUPPORTERS

We're grateful to receive support from the following organisations

Telethon Kids Institute.jpg
Harry Perkins Institute.png
uwa-university-perth-logo.png
curtin.png
 
 
 

NEWS

INVESTORS

If you are an investor and are interested in learning more about what we do and how you can join us in making "simple" procedures simple, please get in touch using the form below, or email nbuckley@veintech.com.au

CONTACT US

Thanks for submitting!

 

We acknowledge the Whadjuk people of the Noongar nation as the traditional custodians of the land on which we live and their continuing connection to land, sea and community. We pay our respects to the people, the culture and the elders past, present and emerging.